Recent Updates
Recently added Catalysts

EMD525797

Phase 1

Solid Tumor | Monoclonal antibody | Oncology |Merck KGaA|Last Updated: May 13, 2016

Success Probability

Subscribe to view

Market & Valuation

Subscribe to view

Trial Design

CONTROLLED
Total Trials1
Total Enrollment27

FDA Designations

No designations recorded

Clinical trial landscape

EMD525797 · 1 trial · 1 indication

Phase 1 1
NCT01327313A Study of EMD525797 in Solid Tumor Patients in JapanSolid Tumor
COMPLETED27 Analytics
PHASE1COMPLETED
A Study of EMD525797 in Solid Tumor Patients in Japan
Solid TumorUnlock trial analytics

Study Endpoints

Primary Endpoints

Number of Subjects With Dose-limiting Toxicities (DLTs)
Baseline up to Week 4

DLT was defined as any Grade 3 or 4 haematological or non-haematological toxicity occurring at any dose level until the end of Week 4, and suspected to be reasonably related to the investigational medicinal product by the Investigator and/or Sponsor. Toxicities not considered to be DLTs are as follows- Allergic reactions or anaphylaxis; any Grade 3 or 4 out-of-range laboratory values without any clinical correlate, which were reversible within 7 days, unless the Investigator decided this event is clinically significant. For this reason Grade 3 or 4 out-of-range laboratory values must be re-assessed within 7 days. In case the Investigator provides the subject any treatment(s) due to the out-of-range laboratory values, the event was regarded as a DLT.

Maximum Observed Serum Concentration (Cmax): After Single Dose
Pre-dose, hour 1(end of infusion [EOI]), 4, 8, 24, 48, and 96 hours after start of infusion at Week 1
Maximum Observed Serum Concentration (Cmax) of EMD 525797:After Multiple Dose
Pre-dose, hour 1 (EOI), 4, 8, 24, 48, and 96 hours after start of infusion at Week 5
Area Under the Curve From Time Zero to Last Quantifiable Concentration(AUC0-t) of EMD 525797: After Single Dose
Pre-dose, hour 1 (EOI), 4, 8, 24, 48, and 96 hours after start of infusion at Week 1

Area under the serum concentration-time curve from time zero to the last sampling time at which the concentration is at or above Lower limit of quantification (LLQ).

Area Under the Curve From Time Zero to Last Quantifiable Concentration(AUC0-t) of EMD 525797: After Multiple Dose
Pre-dose, hour 1 (EOI), 4, 8, 24, 48, and 96 hours after start of infusion at Week 5

Area under the serum concentration-time curve from time zero to the last sampling time at which the concentration is at or above LLQ.

Total Body Clearance (CL) of EMD 525797: After Single Dose
Pre-dose, hour 1 (EOI), 4, 8, 24, 48, and 96 hours after start of infusion at Week 1

Total body clearance of drug in serum was calculated: as CL= Dose divided by Area under the serum concentration-time curve from time zero to infinity (AUC0-inf).

Total Body Clearance at Steady State (CLss) of EMD 525797
Pre-dose, hour 1 (EOI), 4, 8, 24, 48, and 96 hours after start of infusion at Week 5

Drug clearance is a quantitative measure of the rate at which a drug substance is removed from the blood. CL of drug in serum was calculated as : CL= Dose/ AUC0-inf. Area under the serum concentration-time curve from time zero to infinity (AUC0-inf), calculated as AUC0-t + AUCextra. AUCextra represents an extrapolated value obtained by Clast / λz, where Clast is the calculated serum concentration at the last sampling time point at which the measured serum concentration is at or above LLQ and λz is the elimination rate constant.

Apparent Volume of Distribution (Vz): After Single Dose
Pre-dose, hour 1 (EOI), 4, 8, 24, 48, and 96 hours after start of infusion at Week 1

Apparent volume of distribution during the terminal phase, calculated as Vz = Dose/AUC0-inf multiplied by elimination rate constant \[λz\]) following single dose. Area under the serum concentration-time curve from time zero to infinity, calculated (AUC0-inf) as AUC0-t + AUCextra. AUCextra represents an extrapolated value obtained by Clast / λz, where Clast is the calculated serum concentration at the last sampling time point at which the measured serum concentration is at or above LLQ and λz is the elimination rate constant. And the elimination rate constant obtained from linear regression of the terminal phase of the log transformed concentration-time data. A minimum of three points is required to calculate λz.

Pharmacokinetics of EMD 525797 - Trough Values
Pre-dose, hour 1 (EOI), 4, 8, 24, 48, and 96 hours after start of infusion at Week 5

The observed serum concentration immediately before next dosing determined directly from the serum concentration-time profile of each subject (= trough concentration).

Apparent Volume of Distribution: After Multiple Dose
Pre-dose, hour 1 (EOI), 4, 8, 24, 48, and 96 hours after start of infusion at Week 5

Apparent volume of distribution during the terminal phase, calculated as Vz = Dose/(Area under the serum concentration-time curve within one complete dosing interval \[AUCtau\]\* λz) following multiple dose.

Secondary Endpoints

Number of Subjects With Overall Tumor Response
Baseline up to Week 36
Number of Subjects With Clinical Benefit
Baseline up to Week 36
Progression-free Survival (PFS)
From first dosing date until disease progression or death, maximum up to Week 36
Unlock Study Endpoints

Study Design & Arms

AllocationNON_RANDOMIZED
MaskingNONE
ModelPARALLEL
PurposeTREATMENT

Treatment Arms

ArmTypeDescription
EMD525797 250 milligram (mg)EXPERIMENTAL -
EMD525797 500 mgEXPERIMENTAL -
EMD525797 1000 mgEXPERIMENTAL -
EMD525797 1500 mgEXPERIMENTAL -

Interventions

NameTypeDescription
EMD525797BIOLOGICALSubjects will receive 250 milligram (mg) of EMD525797 intravenously every 2 weeks, until progressive disease (PD), unacceptable toxicity or withdrawal of consent.
Unlock Study Design Details

Eligibility Criteria

Age Range20 Years to N/A
SexALL
Healthy VolunteersNo
Study Sites1

Inclusion Criteria: * Age greater than or equal to (\>=) 20 years * Histologically or cytologically proven advanced or metastatic solid tumor * Evidence of progressive disease after standard chemotherapy or no standard chemotherapy * Confirmation of availability of formalin-fixed paraffin-embedded ...

Countries:Japan
Unlock Eligibility Criteria

Competitive Landscape -Other Solid Tumors 9 trials (matched to "Solid Tumor")

Frequently asked questions about EMD525797

What is EMD 525797 used for?

EMD 525797 is an investigational monoclonal antibody being studied in oncology. It has been evaluated in clinical trials for colorectal and ovarian cancer patients with liver metastases, solid tumors, metastatic colorectal cancer, and prostate cancer with bone metastases. All trials completed Phase 1.

What does EMD 525797 target?

EMD 525797 is a monoclonal antibody, but its specific molecular target has not been disclosed in the available clinical trial information. The drug is being investigated for its potential effects in various cancer types, including colorectal, ovarian, and prostate cancer.

Who makes EMD 525797?

EMD 525797 is being developed by Merck KGaA, a German multinational pharmaceutical company. The company's stock is traded over-the-counter under the ticker symbol MKGAF.

What phase is EMD 525797 in?

EMD 525797 is in Phase 1 clinical development. All four clinical trials listed for the drug are Phase 1 studies and have been completed. The drug is investigational and has not been approved by regulatory authorities.

What clinical trials is EMD 525797 in?

EMD 525797 has been studied in four completed Phase 1 trials: NCT00848510 in colorectal and ovarian cancer patients with liver metastases, NCT00958477 in prostate cancer with bone metastases, NCT01008475 in combination with cetuximab and irinotecan in K-ras wild type metastatic colorectal cancer, and NCT01327313 in solid tumor patients in Japan.

Is EMD 525797 the same as abituzumab?

EMD 525797 is also known as abituzumab, a monoclonal antibody developed by Merck KGaA. The drug has been investigated in Phase 1 trials for various cancers, including colorectal, ovarian, and prostate cancer.